#USA #Dallas #Lung Cancer #Cizzle Bio #CIZ1B Test

Cizzle Bio Launches CIZ1B Biomarker Blood Test for Early Lung Cancer Detection

Cizzle Bio, Inc., a biotechnology company based in Texas, has recently launched its groundbreaking CIZ1B Biomarker Blood Test specifically designed for the early detection of lung cancer. With the test now available to licensed healthcare providers in the Dallas-Fort Worth and San Antonio areas, it represents a significant advancement in cancer diagnostics that aims to improve patient outcomes.

The CIZ1B biomarker blood test is the result of extensive research and has completed laboratory validation at OmniHealth Diagnostics. This launch is considered the first step in a larger strategy for U.S. commercialization, as Cizzle Bio plans to expand its reach through additional partnerships with CLIA-certified laboratories across the nation in the coming months.

Currently, lung cancer is the leading cause of cancer-related deaths in the United States, with many cases diagnosed at late stages when treatment options are severely limited. Although low-dose computed tomography (LDCT) screenings are recommended for high-risk individuals, participation in such screenings remains low. Physicians encounter difficulties in evaluating patients with indeterminate lung nodules and other concerning clinical findings, therefore adding more pressure on the need for effective screening tools.

Cizzle Bio’s CIZ1B test addresses this critical unmet need by offering healthcare providers a biomarker-based approach that augments existing diagnostic methods like LDCT, leading to more informed clinical decisions. The test employs an ELISA-based immunoassay that detects a protein variant indicative of early-stage lung cancer from a small blood sample. The technology behind this innovative test is rooted in over thirty years of research originating from the University of York and is currently undergoing further validation in clinical studies with leading NCI-designated cancer centers, including the Moffitt Cancer Center.

Bill Behnke, CEO of Cizzle Bio, remarked on the importance of this launch, stating, “Making this test available to healthcare providers marks an important advancement in bringing innovative biomarker testing into clinical practice. Our goal is to provide physicians with an additional tool that complements established diagnostic procedures and supports earlier evaluation of patients at risk for lung cancer.” He expressed optimism about expanding access through a growing network of CLIA-certified laboratory partners.

The decision to launch the CIZ1B test in the Dallas-Fort Worth and San Antonio markets was strategic. These regions house large populations at risk for lung cancer, robust physician networks, and hold significant importance in the broader commercialization objectives of Cizzle Bio. The company aims to ensure that the CIZ1B Biomarker Blood Test supports the clinical decision-making of healthcare providers and should be interpreted alongside a patient’s medical history, imaging studies, and additional clinical parameters.

Cizzle Bio, Inc. is not only focused on lung cancer; its mission extends to revolutionizing cancer diagnostics through the advancement of biomarker blood tests targeted at both lung and gastric cancers. Their commitment is to equip clinicians and empower patients by providing them with innovative and compassionate solutions that improve health outcomes. Cizzle Bio holds exclusive licensing rights to the CIZ1B blood test for lung cancer in the United States, Canada, and the Caribbean, accompanied by worldwide exclusive rights for its DEX-G2 gastric cancer test. With plans to commercialize both diagnostics in the U.S. clinical environment, Cizzle Bio is at the forefront of transforming cancer detection.source

For those interested in more information, healthcare providers in the affected areas can learn how to order the CIZ1B Biomarker Blood Test by visiting cizzlebio.com. Patients can find further details about the test by navigating to cizzlebio.com.